Intensive Depression Treatment in West Palm Beach is now available at HOPE Accelerated Care. For most people with depression, the path through treatment is sequential. Try one medication. Give it time. Adjust the dose. Try another. Add a second medication. Start therapy. When one approach doesn’t work, move to the next — typically over months or years, one step at a time.
For some patients, that pace isn’t a limitation of the science. It’s a mismatch between the severity of what they’re facing and the intensity of the response. There is a category of depression — severe, persistent, resistant to multiple conventional treatments — that calls for something more comprehensive, more immediate, and more clinically sophisticated than standard outpatient care. Hope Therapeutics in West Palm Beach was built for exactly that patient.
What Makes Accelerated Care Different
Standard mental healthcare treats depression one intervention at a time. A medication is tried, evaluated, adjusted, and if insufficient, replaced or supplemented. A therapy modality is introduced. Progress is measured in weekly appointments. This model works for a meaningful portion of patients with depression — but for those with severe or treatment-resistant presentations, it often produces partial benefit at best, or extends the period of suffering while the next approach is assembled.
Accelerated care works differently. Rather than applying treatments sequentially, Hope Accelerated Care brings together the three most clinically established neuroplastic interventions — TMS, IV Ketamine, and SPRAVATO® — in a coordinated, intensive format designed to produce rapid, comprehensive neuroplastic change.
The scientific basis for this approach lies in understanding how these treatments interact at a biological level. TMS works by directly stimulating neural circuits involved in mood regulation, normalizing activity in the dorsolateral prefrontal cortex and strengthening connectivity across mood-regulating networks. IV Ketamine and SPRAVATO® both act through the glutamate system, promoting synaptogenesis and activating neuroplastic pathways that conventional antidepressants cannot reach. (1) When delivered in a coordinated sequence, these interventions may create a broader and more sustained neuroplastic environment than any single treatment produces alone — a window of enhanced brain plasticity during which therapeutic change can occur more rapidly and more durably. (2)
This is the clinical logic behind intensive multi-modal care: not more of one thing, but the strategic combination of treatments that each address different aspects of the same underlying biology.
The Accelerated TMS Protocol
One of the distinguishing features of Hope Accelerated Care is access to accelerated TMS protocols — treatment formats that compress what is traditionally a four-to-six-week daily schedule into a significantly shorter intensive period, without compromising the underlying efficacy. Research published in Neuropsychopharmacology found that accelerated TMS protocols show similar efficacy and safety profiles to FDA-cleared standard TMS, while substantially reducing the total treatment timeline. (2)
The FDA cleared an accelerated deep TMS protocol for major depressive disorder in 2025, recognizing the growing evidence base for intensive formats. For patients who cannot wait weeks for a standard TMS course to run its full length — whether because their symptoms are severe, because life circumstances demand more urgent results, or simply because a compressed timeline is preferable — the accelerated format offers a clinically supported alternative.
Accelerated TMS is not appropriate for every patient, and the decision to use it versus a standard schedule is made as part of a comprehensive clinical evaluation. But its availability at Hope Therapeutics in West Palm Beach means that patients who need the fastest possible path to meaningful symptom relief have an option that didn’t exist in this form a decade ago.
IV Ketamine and SPRAVATO® in an Intensive Context
Within an accelerated care program, the speed of ketamine and esketamine is a specific clinical advantage. For patients experiencing severe depression or suicidal ideation, waiting weeks for a treatment to build toward effect is not an acceptable clinical timeline. Both IV Ketamine and SPRAVATO® can produce meaningful changes in symptoms within hours to days, (3) and may provide an initial foundation on which TMS and longer-term therapeutic work can build.
SPRAVATO® received FDA approval as a monotherapy for treatment-resistant depression in January 2025 — a milestone that confirmed its standing as a clinically validated first-line option for adults who haven’t responded to at least two antidepressants, not merely an adjunct to other treatments. (4) In the context of an intensive program, it offers FDA-approved, insurance-eligible rapid relief that can be coordinated alongside TMS sessions within the same treatment framework.
The combination of these treatments is not applied uniformly. A patient’s specific diagnosis, clinical history, current medications, and treatment goals all shape how these modalities are deployed and sequenced. Intensive does not mean indiscriminate — it means comprehensive, with each element chosen for clinical reasons and monitored carefully throughout.
Who Hope Accelerated Care Is For
Not every patient with depression needs accelerated care. For patients who are responding adequately to antidepressants, or who are early in their treatment journey with first-line options still to explore, standard outpatient care through a general or psychiatric practice is often appropriate.
Hope Accelerated Care is specifically designed for patients who have moved beyond that point. The program is most relevant for people experiencing severe depression that has not responded meaningfully to multiple medications or treatment approaches, patients with persistent suicidal ideation where the urgency of symptom relief is a direct clinical consideration, and those whose depression has been severe and treatment-resistant enough that incremental approaches have consistently fallen short.
It is also relevant for patients who have tried individual neuroplastic treatments elsewhere — TMS at one clinic, ketamine at another — without the kind of coordinated, intensive program structure that may produce better outcomes than isolated sessions. The coordination matters as much as the treatments themselves.
The Clinical Environment at 1515 N Flagler Drive
Hope Therapeutics is located at 1515 N Flagler Drive, Suite 800 in West Palm Beach — a setting designed specifically for the delivery of intensive neuroplastic treatments, with the equipment, staffing, and monitoring infrastructure that this level of care requires.
The clinical team includes expertise in interventional psychiatry, TMS, IV infusion therapy, psychotherapy, and operational management of complex treatment programs. This isn’t a general psychiatric practice that offers TMS as an add-on. It is a specialty clinic where treatment-resistant and severe presentations are the primary focus — and where the full clinical toolkit is available, evaluated, and applied in coordination.
For patients in Palm Beach County — and for those traveling to West Palm Beach from Boca Raton, Delray Beach, Lake Worth, Boynton Beach, Wellington, or Jupiter — Hope Therapeutics represents access to a level of intensive, evidence-based mental health care that isn’t widely available in the region.
Starting the Conversation
Every patient who begins a program at Hope Accelerated Care starts with a comprehensive evaluation. That evaluation reviews the full arc of prior treatment, assesses current clinical presentation, considers any co-occurring conditions, and determines which combination of treatments — and in what format — is most appropriate.
The goal is not to apply the same intensive program to everyone. It is to match the right level of intensity to the right patient at the right moment — and for patients facing severe, treatment-resistant depression, that match can genuinely change what’s possible.
Learn more about other alternatives to depression treatment in West Palm Beach below.
https://hopetherapeutics.com/ketamine-therapy-for-depression-in-west-palm-beach
https://hopetherapeutics.com/tms-therapy-for-depression-in-west-palm-beach
https://hopetherapeutics.com/emdr-therapy-west-palm-beach-fl
https://hopetherapeutics.com/intranasal-ketamine-in-west-palm-beach-fl
https://hopetherapeutics.com/iv-ketamine-therapy/west-palm-beach-fl
https://hopetherapeutics.com/ketamine-assisted-psychotherapy-west-palm-beach/
https://hopetherapeutics.com/medication-management-west-palm-beach-fl/
https://hopetherapeutics.com/psychotherapy-west-palm-beach-fl/
https://hopetherapeutics.com/talk-therapy-west-palm-beach-fl/
https://hopetherapeutics.com/telehealth-mental-health-west-palm-beach/
https://hopetherapeutics.com/locations/west-palm-fl/
https://hopetherapeutics.com/ptsd-treatment-in-west-palm-beach/
https://kmdclinics.com/ketamine-treatment-west-palm-beach/
https://hopetherapeutics.com/expert-mental-health-care-in-palm-beach-county/
Take the Next Step
If you or someone you care about is facing severe or treatment-resistant depression in the West Palm Beach area, Hope Therapeutics in West Palm Beach offers a comprehensive consultation to determine whether intensive multi-modal treatment — including TMS, IV Ketamine, SPRAVATO®, Ketamine-Assisted Psychotherapy, or Medication Management — is the right next step.
Hope Therapeutics 1515 N Flagler Dr, Suite 800 | West Palm Beach, FL 33401 📞 561-372-8705 Schedule a Consultation
References
- Kang MJY, Nepomuceno L, et al. The mechanisms behind rapid antidepressant effects of ketamine: a systematic review with a focus on molecular neuroplasticity. Frontiers in Psychiatry. 2022;13:860882. DOI: 10.3389/fpsyt.2022.860882. Available at: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2022.860882/full
- van Rooij SJH, Arulpragasam AR, McDonald WM, Philip NS. Accelerated TMS — moving quickly into the future of depression treatment. Neuropsychopharmacology. 2023. DOI: 10.1038/s41386-023-01599-z. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10700378/
- Peiris TE, Pokhrel A, Paudel Y. Ketamine for unipolar depression: a systematic review of efficacy and safety. The International Journal of Psychiatry in Medicine. 2025. DOI: 10.1177/10398562251328805. Available at: https://journals.sagepub.com/doi/10.1177/10398562251328805
- Johnson & Johnson. SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression. January 21, 2025. Available at: https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression
- Fiorillo A, Demyttenaere K, Martiadis V, Martinotti G. Treatment resistant depression (TRD): epidemiology, clinic, burden and treatment. Frontiers in Psychiatry. 2025;16. DOI: 10.3389/fpsyt.2025.1588902. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958960/
The information in this article is intended for educational purposes only and does not constitute medical advice. The treatments described may not be appropriate for every individual. Please consult a qualified healthcare provider to discuss your specific situation, medical history, and treatment options before making any decisions about your care.
